Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki

Broadening its oncolytic virus and tumour antigen-based immuno-oncology approach across enveloped viruses OXFORD, England and HELSINKI, Sept. 2, 2019 -- (Healthcare Sales & Marketing Network) -- Valo Therapeutics Limited (Valo Tx), an immuno-oncology c... Biopharmaceuticals, Drug Delivery, Oncology, Acquisitions Valo Therapeutics, PeptiENV
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news